Evonile Pharma schedules Q2 and half-year FY2026-27 earnings call

Board & Shareholder Meetings View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹1792.00

prior close

₹1821.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector+2.0%+0.8% vs sector

On the reaction day the stock moved 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.1

15m

-0.8

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7pendingpending+2.0+0.8

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Evonile Pharma will hold an investor and analyst earnings call on November 4, 2026, from 2:30 PM to 3:30 PM IST, to discuss unaudited results for the quarter and half-year ended September 30, 2026. Registration and dial-in details are provided in the filing. No financial results are announced.

Likely market impact

This is only a briefing notice, with no financial figures. Management's comments on November 4 could prompt investor reaction and short-term share-price volatility.